360 related articles for article (PubMed ID: 31129499)
1. Somatostatin receptor targeting with hydrophilic [
Makris G; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
Nucl Med Biol; 2019 Apr; 71():39-46. PubMed ID: 31129499
[TBL] [Abstract][Full Text] [Related]
2. NOTA and NODAGA [
Makris G; Radford LL; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
Bioconjug Chem; 2018 Dec; 29(12):4040-4049. PubMed ID: 30412382
[TBL] [Abstract][Full Text] [Related]
3. Development and Preclinical Evaluation of
Makris G; Bandari RP; Kuchuk M; Jurisson SS; Smith CJ; Hennkens HM
Mol Imaging Biol; 2021 Feb; 23(1):52-61. PubMed ID: 32886303
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of a
Radford L; Gallazzi F; Watkinson L; Carmack T; Berendzen A; Lewis MR; Jurisson SS; Papagiannopoulou D; Hennkens HM
Nucl Med Biol; 2017 Apr; 47():4-9. PubMed ID: 28043006
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of Re/
Radford LL; Papagiannopoulou D; Gallazzi F; Berendzen A; Watkinson L; Carmack T; Lewis MR; Jurisson SS; Hennkens HM
Bioorg Med Chem; 2019 Feb; 27(3):492-501. PubMed ID: 30594453
[TBL] [Abstract][Full Text] [Related]
6. Direct labeling of a somatostatin receptor antagonist via peptide cyclization with Re,
Wang J; Makris G; Kuchuk M; Radford L; Gallazzi F; Lewis MR; Jurisson SS; Hennkens HM
Nucl Med Biol; 2021; 94-95():46-52. PubMed ID: 33515899
[TBL] [Abstract][Full Text] [Related]
7. p-NCS-Bn-NODAGA as a bifunctional chelator for radiolabeling with the
H A Kankanamalage P; Hoerres R; Ho KV; Anderson CJ; Gallazzi F; Hennkens HM
Nucl Med Biol; 2022; 108-109():1-9. PubMed ID: 35144046
[TBL] [Abstract][Full Text] [Related]
8. Novel [
Qiao Z; Xu J; Gonzalez R; Miao Y
Mol Pharm; 2020 Sep; 17(9):3581-3588. PubMed ID: 32663011
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and preclinical evaluation of rhenium and technetium-99m "4 + 1" mixed-ligand complexes bearing quinazoline derivatives as potential EGFR imaging agents.
Kiritsis C; Shegani A; Makrypidi K; Roupa I; Lazopoulos A; Panagiotopoulou A; Triantopoulou S; Paravatou-Petsotas M; Pietzsch HJ; Pelecanou M; Papadopoulos M; Pirmettis I
Bioorg Med Chem; 2022 Nov; 73():117012. PubMed ID: 36155319
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Characterization, and In Vitro Evaluation of New (99m)Tc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach.
Li Y; Ma L; Gaddam V; Gallazzi F; Hennkens HM; Harmata M; Lewis MR; Deakyne CA; Jurisson SS
Inorg Chem; 2016 Feb; 55(3):1124-33. PubMed ID: 26789775
[TBL] [Abstract][Full Text] [Related]
12. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model.
Rylova SN; Stoykow C; Del Pozzo L; Abiraj K; Tamma ML; Kiefer Y; Fani M; Maecke HR
PLoS One; 2018; 13(4):e0195802. PubMed ID: 29668724
[TBL] [Abstract][Full Text] [Related]
13. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F
Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172
[TBL] [Abstract][Full Text] [Related]
14. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference.
Fani M; Del Pozzo L; Abiraj K; Mansi R; Tamma ML; Cescato R; Waser B; Weber WA; Reubi JC; Maecke HR
J Nucl Med; 2011 Jul; 52(7):1110-8. PubMed ID: 21680701
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of new mixed "2 + 1" Re,
Shegani A; Ischyropoulou M; Roupa I; Kiritsis C; Makrypidi K; Papasavva A; Raptopoulou C; Psycharis V; Hennkens HM; Pelecanou M; Papadopoulos MS; Pirmettis I
Bioorg Med Chem; 2021 Oct; 47():116373. PubMed ID: 34467870
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
17. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with
Ku A; Chan C; Aghevlian S; Cai Z; Cescon D; Bratman SV; Ailles L; Hedley DW; Reilly RM
Mol Pharm; 2019 Aug; 16(8):3559-3568. PubMed ID: 31242384
[TBL] [Abstract][Full Text] [Related]
18. Versatile synthetic approach to new bifunctional chelating agents tailor made for labeling with the fac-[M(CO)(3)](+) core (M = Tc, (99m)Tc, Re): synthesis, in vitro, and in vivo behavior of the model complex [M(APPA)(CO)(3)] (APPA = [(5-amino-pentyl)-pyridin-2-yl-methyl-amino]-acetic acid).
Stichelberger A; Waibel R; Dumas C; Schubiger PA; Schibli R
Nucl Med Biol; 2003 Jul; 30(5):465-70. PubMed ID: 12831983
[TBL] [Abstract][Full Text] [Related]
19. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
Brand C; Longo VA; Groaning M; Weber WA; Reiner T
Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
[TBL] [Abstract][Full Text] [Related]
20. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
